Chairman, Non-Executive Director | BPharm, DipEc, MPS
Ken Windle worked 30 years with Glaxo/Glaxo Wellcome (now gsk) in International positions including Member of the Group’s Executive Committee. This career in-cluded Head of Global Commercialisation based in London, CEO of subsidiaries in UK, Australia, and Regional President Asia Pacific. He was Chairman and CEO of Advent Pharmaceuticals Pty Ltd which he co-founded in 2001 and sold in2018. He was Director of Aus Bio Ltd, Chairman of their R&D Committee, Deputy Chair of Acrux, and NED of NZ Pharmaceuticals. He is Chairman of RMIT’s PAC and NED of Opal. He served 8 years as a Member of Innovation Australia which included Chairman of the Board’s COMET and P3 Committees, member of IIIF Committee, and PISG Working Group. He was Chairman of the working group in Victorian Govt’s. Biotechnology Strategic Development Plan. Graduating from Otago Uni-versity in Pharmacy and pharmacology, he further studied Economics at Massey University, and completed the Executive Programme at London Business School. Mr Windle has previously served as Consultant to the (Australian) Prime Minister's Science Council on Industry Development, Director of the (Singapore) Economic Development Board EDB, and (Singapore’s) Committee on Competitiveness. He was for 2 three year terms Chairman of the APMA (now Medicines Australia), a member of the Pharmaceuticals Industry Advisory Committee, a member of Phar-maceuticals Industry Action Agenda (PIAAG), member of the Pharmaceuticals In-dustry Strategy Group (PISG), and has been twice a winner of the Governor of Victoria’s Export Prize.